1Rodriguez MM,Guerrero RF.Elevated concentrations of Creactive protein in subjects with type 2 diabetes mellitus are moderately influenced by glycemic control[J].J Endocrinol Invest,2003,26(3):216-221.
2Hashimoto M,Akishita M,Eto M,et al.The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation[J].Int J Obes Relat Metab Disord,1998,22(5):477-484.
3Haffner SM,Miettinen H,Stern MP.The homeostasis model in the San Antonio Heart Study[J].Diabetes Care,1997,20(6):1087-1092.
4Celermajer DS,Sorensen KE,Gooch VM,et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis[J].Lancet,1992,340(5):1111-1115.
5Celermajer DS.Endothelial dysfunction:does it matter? Is it reversible?[J].J Am Coll Cardiol,1997,30(2):325-333.
6Cmes MC.C-reactive protein:a new golden marker of cardiovascular risk[J].Rev Port Cardiol,2002,21 (11):3726-3727.
7Li JJ,Fang CH.C-reactive protein in not only an in flammatory marker but also a direct cause of cardiovascular disease[J].Med Hypotheses,2004,62 (4):499-506.
8Labarrere CA,Zaloga GP.C-reactive protein:from innocent bystander to pivotal wediator of atherosclerosis[J].Am J Med,2004,117(7):499-507.
1Hanson RL, Imperatore G, Bennett PH, et al. Components of the “metabolic syndrome”and incidence of type 2 diabetes. Diabetes, 2002, 51: 3120-3127.
2Meigs JB. Invited commentary: insulin resistance syndrome?Syndrome X? Multiple metabolic syndrome? A syndrome at all?Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol, 2000, 152: 908-911.
3Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation, 2002, 105: 564-569.
4van Oostrom AJ, van Wijk J, Cabezas MC. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs, 2004, 64 Suppl 2: 19-41.
1Accili D, Arden KC. Foxos at the crossroads of cellular metabolism, differentiation, and transformation [J ]. Cell, 2004, 117(4) :421-426.
2Abel ED,Peroni O,Kim JK,et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver[J]. Nature, 2001,409( 6821 ) : 729-733.
3Tozzo E, Shepherd PR, Gnudi L, et al. Transgenic GLUT-4 overexpression in fat enhances glucose metabolism: preferential effect on fatty acid synthesis[J]. Am J Physiol, 1995,268(5 Pt 1) :E956-64.
4Garvey WT,Maianu L, Huecksteadt TP,et al. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin dependent diabetes mellitus and obesity[J]. J Clin lnvest, 1991, 87(3) : 1072-1081.
5Samuel VT, Choi CS, Phillips TG, et al. Targeting Foxol in mice using antisense oligonucleotide improves hepatic and peripheral insulin action[J]. Diabetes, 2006,55 (7) : 2042-2050.
6Nakae J, Cao Y, Oki M, et al. Forkhead transcription factor Foxol in adipose tissue regulates energy storage and expenditure[J]. Diabetes, 2008,57 (3): 563-576.
7Farmer SR. The forkhead transcription factor Foxol: a possible link between obesity and insulin resistance[J]. Mol Cell. 2003, 11(1):6-8.
8Kloting N, Bluher M, Kloting 1. The polygenetically inherited metabolic syndrome of WOKW rats is associated with insulin resistance and ahered gene expression in adipose tissue [J]. Diabetes Metab Res Rev,2006,22(2):146-154.
